Rapid decline of neutralizing antibodies is associated with decay of IgM in adults recovered from mild COVID-19.
Adult
Aged
Antibodies, Neutralizing
/ blood
COVID-19
/ complications
Female
Fever
/ etiology
Humans
Immunoglobulin G
/ blood
Immunoglobulin M
/ blood
Male
Middle Aged
Neutralization Tests
Nucleocapsid Proteins
/ immunology
Protein Domains
/ immunology
Protein Multimerization
/ immunology
SARS-CoV-2
/ immunology
Severity of Illness Index
Spike Glycoprotein, Coronavirus
/ chemistry
Time Factors
Young Adult
COVID-19
IgG
IgM
SARS-CoV-2
antibody avidity
mild infection
neutralizing antibodies
Journal
Cell reports. Medicine
ISSN: 2666-3791
Titre abrégé: Cell Rep Med
Pays: United States
ID NLM: 101766894
Informations de publication
Date de publication:
20 04 2021
20 04 2021
Historique:
received:
17
11
2020
revised:
11
02
2021
accepted:
24
03
2021
pubmed:
13
4
2021
medline:
13
4
2021
entrez:
12
4
2021
Statut:
ppublish
Résumé
The fate of protective immunity following mild severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection remains ill defined. Here, we characterize antibody responses in a cohort of participants recovered from mild SARS-CoV-2 infection with follow-up to 6 months. We measure immunoglobulin A (IgA), IgM, and IgG binding and avidity to viral antigens and assess neutralizing antibody responses over time. Furthermore, we correlate the effect of fever, gender, age, and time since symptom onset with antibody responses. We observe that total anti-S trimer, anti-receptor-binding domain (RBD), and anti-nucleocapsid protein (NP) IgG are relatively stable over 6 months of follow-up, that anti-S and anti-RBD avidity increases over time, and that fever is associated with higher levels of antibodies. However, neutralizing antibody responses rapidly decay and are strongly associated with declines in IgM levels. Thus, while total antibody against SARS-CoV-2 may persist, functional antibody, particularly IgM, is rapidly lost. These observations have implications for the duration of protective immunity following mild SARS-CoV-2 infection.
Identifiants
pubmed: 33842901
doi: 10.1016/j.xcrm.2021.100253
pii: S2666-3791(21)00069-0
pmc: PMC8020863
doi:
Substances chimiques
Antibodies, Neutralizing
0
Immunoglobulin G
0
Immunoglobulin M
0
Nucleocapsid Proteins
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
100253Subventions
Organisme : NIAID NIH HHS
ID : K08 AI135072
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI140951
Pays : United States
Informations de copyright
© 2021 The Author(s).
Déclaration de conflit d'intérêts
The authors declare no competing interests.